Benitec Biopharma
BNTC
86 hedge funds and large institutions have $443M invested in Benitec Biopharma in 2026 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 35 increasing their positions, 22 reducing their positions, and 10 closing their positions.
743% more capital inflows, than outflows
Capital inflows: $47.7M | Capital outflows: $5.66M
59% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 22
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
1.91% more ownership
Funds ownership: 94.55% → 96.46% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less funds holding
Funds holding: 88 → 86 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Simplify Asset Management
Las Vegas,
Nevada
|
+$5.26M |
| 2 |
Millennium Management
New York
|
+$3.19M |
| 3 |
BlackRock
New York
|
+$2.63M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.04M |
| 5 |
Schonfeld Strategic Advisors
New York
|
+$975K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Longaeva Partners
Chicago,
Illinois
|
-$1.31M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.07M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$765K |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$450K |
| 5 |
Goldman Sachs
New York
|
-$444K |
BNTC Hedge Fund Activity: Q2 2026 in Review
86 of the 8,355 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q2 2026, worth a combined $443M — up 28% from $346M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new BNTC positions and 10 closed out — a net gain of 1 holder — while 35 added to existing stakes and 22 trimmed.
The largest buyer was Simplify Asset Management, adding an estimated $5.26M. The largest seller was Longaeva Partners, cutting an estimated $1.31M.
- 86 institutional investors held Benitec Biopharma (BNTC) as of Q2 2026, down from 88 in Q1 2026.
- Funds reported $443M of Benitec Biopharma stock for Q2 2026, up 28% quarter-over-quarter.
- 11 funds opened new Benitec Biopharma positions in Q2 2026 and 10 closed out, a net change of +1 holder.
- The largest Benitec Biopharma buyer in Q2 2026 was Simplify Asset Management, an estimated $5.26M added.
- The largest Benitec Biopharma seller in Q2 2026 was Longaeva Partners, an estimated $1.31M sold.
Based on aggregated 13F filings for Q2 2026.